Nektar Therapeutics (NKTR): Cost of Revenue
$0
Year ended 2025-12-31
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | $30.69M | -9.1% | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | $33.77M | +56.1% | 2025-03-14, From 2023-01-01 |
| 2022-12-31 | $21.64M | -13.1% | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | $24.90M | +27.8% | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | $19.48M | -8.9% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $21.37M | -12.4% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $24.41M | -20.1% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $30.55M | +1.1% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $30.21M | -11.4% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $34.10M | +19.5% | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | $28.53M | -25.9% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $38.51M | +26.6% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $30.43M | +39.0% | 2015-02-26, From 2012-01-01 |
| 2011-12-31 | $21.89M | -14.7% | 2014-02-27, From 2011-01-01 |
| 2010-12-31 | $25.67M | -17.1% | 2013-03-01, From 2010-01-01 |
| 2009-12-31 | $30.95M | n/a | 2012-02-29, From 2009-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Nektar Therapeutics (NKTR) | 2025-12-31 | $0 | -100.0% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $6.34M | +52.3% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $20.75M | +1.0% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $6.57M | +16.9% |
| Journey Medical Corp (DERM) | 2025-12-31 | $20.92M | +0.2% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $274.0K | -55.5% |
| Nuvation Bio Inc. (NUVB) | 2024-12-31 | $7.08M | n/a |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $20.92M | +0.2% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $18.55M | +3.8% |
Compare NKTR, AGIO, AYTU, OCUL side by side · Screen every company in Pharmaceutical Preparations ↗